ArticleJournal of the American College of Surgeons2025
Tranexamic Acid and Systemic Complement Activation in Traumatic Brain Injury Patients.
Article in Journal of the American College of Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionTraumatic brain injury (TBI) is a leading cause of trauma-related death. A pre-hospital 2-gram bolus of tranexamic acid (TXA) has shown mortality benefit but no reduction in brain bleed size on cross-sectional imaging, suggesting an alternative mechanism may explain its effect. Plasmin activates complement proteins C3 and C5, and complement activation is linked to worse outcomes in animal TBI models.
methods40 adult trauma patients with imaging-confirmed TBI, randomized to TXA (2-gram bolus) or placebo in a pre-hospital trial. Plasma was analyzed at presentation (ED), 6 hours, and 24 hours. Complement activation and regulatory markers, coagulation/fibrinolysis parameters, and plasmin generation were assessed using complement multiplex, ELISA, and clinical laboratory testing. Pairwise comparisons were made using ANOVA with significance set at p<0.05.
resultsPatients were mostly male (85%) and white (72.5%), with a median age of 36.5 years. TXA significantly reduced sC5b-9 levels at ED arrival (191.5±143.4 ng/mL TXA vs. 333.9±404.4 ng/mL placebo, p=0.04) and C5a at 24 hours. Factor H levels were higher in the TXA group at ED arrival (226.2±103.6 ng/mL TXA vs. 186.0±38.0 ng/mL placebo, p=0.03). D-dimer levels were significantly lower in the TXA group at 6 hours (4.8±5.1 µg/mL TXA vs. 8.4±7.5 µg/mL placebo, p=0.04). Plasmin-antiplasmin levels and thromboelastography LY30 showed no differences.
conclusionsA pre-hospital 2-gram TXA bolus appears to significantly reduce complement activation and preserve Factor H, a key complement regulatory protein, suggesting TXA's benefit may involve complement modulation. TXA reduced D-dimer, a downstream product of plasmin activation, indicating complement modulation could be due to a plasmin-mediated process. Further studies are needed to determine if this mechanism is plasmin-mediated and applicable to other dosing regimens and non-TBI trauma populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.